State of the art: radiolabeled microspheres treatment for liver malignancies

Bibliography

• Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30(5):969-77
   PubMedGoogle Scholar
• Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000;45(4):1023-33
   PubMedGoogle Scholar
• Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46(2):487-98
   PubMedGoogle Scholar
• Kennedy A, Nutting C, Coldwell D, Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552-63
   PubMed Web of Science ®Google Scholar
• Kennedy A, Nag S, Salem R, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys 2006;68:13-23
   Google Scholar
• Blanchard RJ, Grotenhuis I, Lafave JW, Treatment of experimental tumors; utilisation or radioactive microspheres. Arch Surg 1964;89:406-10
   PubMed Web of Science ®Google Scholar
• Mantravadi RVP, Spigos DG, Walter ST, Intraarterial Yttrium 90 in the treatment of hepatic malignancy. Radiology 1982;142(3):783-86
   PubMedGoogle Scholar
• Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006;66(2):62-73
   Google Scholar
• Kennedy AS, Salem R. Comparision of two 90 yttrium microsphere agents for hepatic artery brachytherapy. Proceedings of the 14th International Congress on Anti-Cancer Treatment; 2003. p. 156
   Google Scholar
• Vente MA, Wondergem M, van der Tweel I, Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009;19(4):951-9
   PubMedGoogle Scholar
• Mulcahy MF, Lewandowski RJ, Ibrahim SM, Radioembolization of colorectal hepatic metastases using Yttrium-90 microspheres. Cancer 2009;115(9):1849-58
   PubMedGoogle Scholar
• Sato KT, Lewandowski RJ, Mulcahy MF, Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 2008;247(2):507-15
   PubMedGoogle Scholar
• Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med 2007;48:2080-86
   PubMedGoogle Scholar
• Kennedy AS, McNeillie P, Dezarn WA, Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009;74(5):1494-500
   PubMedGoogle Scholar
• Sangro B, Gil-Alzugaray B, Rodriguez J, Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112(7):1538-46
   PubMedGoogle Scholar
• Flamen P, Vanderlinden B, Delatte P, Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol 2008;53(22):6591-603
   PubMedGoogle Scholar
• Biernert M, McCook B, Carr B, 90Y microsphere treatment of unresectable liver metastases: changes in the FDG uptake and tumor size on PET-CT. Eur J Nucl Med Mol Imaging 2005;32:778-87
   PubMedGoogle Scholar
• Marn CS, Andrews JC, Francis IR, Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology 1993;187:125-8
   PubMedGoogle Scholar
• Murthy CS, Nunes R, Szklaruk J, Y-90 microspheres therapy for hepatic malignancy: devices, indications, technical considerations and potential complications. Radiographics 2005;25:S41-55
   PubMed Web of Science ®Google Scholar
• Sharma RA, Van Hazel GA, Morgan B, Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007;25(9):1099-106
   PubMedGoogle Scholar
• Lim L, Gibbs P, Yip D, Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005;35(4):222-7
   PubMedGoogle Scholar
• Lim L, Gibbs P, Yip D, A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005;5:132
   PubMed Web of Science ®Google Scholar
• Wong CY, Salem R, Qing F, Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004;45(11):1892-7
   PubMedGoogle Scholar
• Kennedy AS, Coldwell D, Nutting C, Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006;65(2):412-25
   PubMedGoogle Scholar
• Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006;76(8):696-703
   PubMedGoogle Scholar
• Szyszko T, Al-Nahhas A, Canelo R, Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun 2007;28(1):15-20
   PubMedGoogle Scholar
• Gray B, Van Hazel G, Hope M, Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12(12):1711-20
   PubMedGoogle Scholar
• Ettinger DS, Leichner PK, Siegelman SS, Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapy. Am J Clin Oncol 1985:8(5):413-418
   PubMedGoogle Scholar
• Van Hazel G, Blackwell A, Anderson J, Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88(2):78-85
   PubMedGoogle Scholar
• Van Den Eynde M, Hendlisz A, Peeters M, Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT). ASCO Annual Meeting Proceedings. J Clin Oncol 2009;(27): abstract 4096
   Google Scholar
• Llovet JM, Real MI, Montaña X, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-71
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Kulik LM, Riaz A, A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920-8
   PubMedGoogle Scholar
• Salem R, Lewandowski RJ, Mulcahy MF, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2009. [Epub ahead of print]
   Google Scholar
• Lau WY, Leung WT, Ho S, Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70(5):994-9
   PubMedGoogle Scholar
• Lau WY, Ho S, Leung TW, Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40(3):583-92
   PubMedGoogle Scholar
• Riaz A, Kulik L, Lewandowski RJ, Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49(4):1185-93
   PubMedGoogle Scholar
• Kulik LM, Atassi B, van Holsbeeck L, Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94(7):572-86
   PubMedGoogle Scholar
• Kulik LM, Carr BI, Mulcahy MF, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71-81
   PubMedGoogle Scholar
• Sangro B, Bilbao JI, Boan J, Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66(3):792-800
   PubMedGoogle Scholar
• Kennedy AS, Dezarn WA, McNeillie P, Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31(3):271-9
   PubMedGoogle Scholar
• King J, Quinn R, Glenn DM, Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113(5):921-9
   PubMedGoogle Scholar
• Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007;69(3):800-4
   PubMedGoogle Scholar
• Jakobs TF, Hoffmann RT, Fischer T, Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008;19(5):683-90
   PubMedGoogle Scholar
• Bangash AK, Atassi B, Kaklamani V, 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007;18(5):621-8
   PubMedGoogle Scholar
• Coldwell D. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres. World Congress on Gastrointestinal Cancer [abstract P-102]. Ann Oncol 2006;17(Suppl 6):vi56-
   Google Scholar
• Ibrahim SM, Mulcahy MF, Lewandowski RJ, Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008;113(8):2119-28
   PubMedGoogle Scholar
• Gulec SA, Mesoloras G, Dezarn WA, Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 2007;5:15
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Thurston KG, Goin JE, 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16(12):1641-51
   PubMedGoogle Scholar
• Wong CY, Qing F, Savin M, Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005;16(8):1101-6
   PubMedGoogle Scholar
• Bienert M, McCook B, Carr BI, Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging 2005;32(6):723
   PubMedGoogle Scholar
• Atassi B, Bangash AK, Bahrani A, Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28(1):81-99
   PubMedGoogle Scholar